Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | CA7 | P43166 | 2/20 | 0.54 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.50 |
| ▸ | BACE1 | P56817 | 13/20 | 0.49 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.49 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6747610 | 0.90 | KLK5 (0.49) | CA1CA2CA7KLK5BACE1 | |
| SCHEMBL6747612 | 0.90 | KLK5 (0.49) | CA1CA2CA7KLK5BACE1 | |
| SCHEMBL8283132 | 0.86 | KLK5 (0.64) | CA1CA2CA7KLK5ATM | |
| SCHEMBL13932829 | 0.86 | KLK5 (0.64) | CA1CA2CA7KLK5ATM | |
| SCHEMBL13748497 | 0.86 | KLK5 (0.64) | CA1CA2CA7KLK5ATM | |
| SCHEMBL6747622 | 0.85 | KLK5 (0.52) | KLK5BACE1CYP17A1 | |
| SCHEMBL6747621 | 0.85 | KLK5 (0.52) | KLK5BACE1CYP17A1 | |
| SCHEMBL13538234 | 0.84 | KLK5 (0.51) | KLK5BACE1CYP17A1 | |
| SCHEMBL13538225 | 0.84 | KLK5 (0.51) | KLK5BACE1CYP17A1 | |
| SCHEMBL13538237 | 0.84 | KLK5 (0.51) | KLK5BACE1CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767302-B2 | Reagents and methods for tetrazine synthesis | UNIVERSITY OF DELAWARE (US) | 2023-09-26 | — | — | US | disclosed |
| US-20090048227-A1 | Substituted-1-Phthalazinamines As Vr- 1 Antagonists | MERCK SHARP & DOHME CORP. | 2009-02-19 | — | — | US | disclosed |
| US-20090048227-A1 | Substituted-1-Phthalazinamines As Vr- 1 Antagonists | MERCK SHARP & DOHME CORP. | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048227-A1 | Substituted-1-Phthalazinamines As Vr- 1 Antagonists | TRPV1, TRPV2, TRPV5 | CA1 1151/4885CA2 877/4885CA7 2862/4885 |
| US-11767302-B2 | Reagents and methods for tetrazine synthesis | TST, CYP4F8, CYP4Z1 | CA1 504/4885CA2 2171/4885CA7 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.